| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9153749 | American Heart Journal | 2005 | 7 Pages |
Abstract
The PREVENT IV data will establish whether VG pretreatment with an E2F transcription factor decoy, edifoligide, can improve graft patency and reduce the long-term morbidity and mortality of patients undergoing CABG surgery.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
John H. MD, MS, T. Bruce MD, Diane M. BS, Michael J. MD, Randall K. MD, C. Michael MD, MS, Daniel MD, Todd J. MD, Robert A. MD, Eric D. MD, MPH, Kerry L. PhD, Robert M. MD, Nicholas T. MD, PREVENT IV Investigators PREVENT IV Investigators,